Skip to content
Screener

SG&A at other companies

Eli Lilly logo
Eli LillyLLY
$3.43B+24.6%
Pfizer logo
PfizerPFE
$3.41B-0.1%
Merck & Co. logo
Merck & Co.MRK
$2.9B+9.6%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$582.2M+37.1%
Cytokinetics logo
CytokineticsCYTK
$104.4M+58.8%
Mannkind logo
MannkindMNKD
$58.3M+84.4%

Other financials

Income statement

See full
Revenue$692.0K-97.6%
Gross profit$653.0K-97.7%
Operating income-$26.5M-810%
Net income-$31.8M-1,077%
EPS (diluted)-$0.07-800%

Balance sheet

See full
Cash & equivalents$40.9M-18.7%
Total debt$59.2M-3.6%
Total equity$174.5M+34.8%
Total assets$250.1M+10.9%

Cash flow

See full
Operating cash flow-$9.2M
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$1.1B+191%
Enterprise value$1.12B+187%
P/S26.5×+20.0×

Profitability

See full
Gross margin99.1%0.0pp
Operating margin-131.4%-34.2pp
Net margin-147.4%-32.8pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-40.2%-11.2pp
Debt / equity0.3×-0.1×
Current ratio13.4×+9.2×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001062822-26-000117
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Cost of sales393314763
Research and development, including stock-based compensation of $1,384, $1,620, $2,753, and $3,194 respectively17,44315,74730,19931,050
Selling, general and administrative, including stock-based compensation of $1,952, $1,575, $3,661, and $3,044 respectively9,7509,35018,98420,958
Total operating expenses27,23225,13049,33052,071
(Loss) income from operations(26,540)3,736(27,536)(21,943)
Interest and other expense(2,609)(2,318)(4,199)(4,153)
Interest and other income1,7231,8343,2664,053

Item 1. Financial Statements

FAQ

What is Lexicon Pharmaceuticals's SG&A?
Lexicon Pharmaceuticals (LXRX) reported SG&A of $9.75M in Q2 2026.
How has Lexicon Pharmaceuticals's SG&A changed year-over-year?
Lexicon Pharmaceuticals's SG&A increased by 4.3% year-over-year, from $9.35M to $9.75M.
What is the long-term trend for Lexicon Pharmaceuticals's SG&A?
Over 3 years (2021 to 2025), Lexicon Pharmaceuticals's SG&A has grown at a 4.9% compound annual growth rate (CAGR), from $32.34M to $37.32M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Lexicon Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude